Objective: Fibroblast growth factor receptors (FGFRs) belong to the receptor tyrosine kinase family (RTKs), including four subtypes (FGFR1, 2, 3 and 4). FGFR mutation or overexpression lead to its continuous activation, which is closely related to tumorigenesis, tumor development and patient poor prognosis. However, up to now, the expression of FGFR family proteins in fibroblast/myofibroblast tumors has not been investigated. Methods: Eighty-nine cases of benign and malignant tumors from 2016 to 2019 were collected, including 17 cases of solitary fibrous tumor, 16 cases of dermatofibrosarcoma protuberans (DFSP), 22 cases of aggressive fibromatosis, 27 cases of undifferentiated sarcomas and 7 cases of nodular fasciitis. The expression of FGFR1, FGFR2, FGFR3, FGFR4 protein was detected by immunohistochemistry (IHC), and the difference of positive rate was analyzed by Fisher’s exact test. Results: No expression of FGFR2 or FGFR4 was detected. FGFR1 was highly expressed in solitary fibrous tumor (16/17, 94.1%) and DFSP (11/16, 68.8%), but negative in nodular fasciitis and undifferentiated sarcomas. The positive rate in either solitary fibrous tumor (16/17, 94.1%) or DFSP were significantly different from that in undifferentiated sarcomas and aggressive fibromatosis. The positive staining of FGFR3 was detected in solitary fibrous tumor (8/17, 94.1%), DFSP (11/16, 68.8%), aggressive fibromatosis (19/22, 86.4%), undifferentiated sarcomas (27/27, 100%) and nodular fasciitis (7/7, 100%), respectively. Conclusion: Immunohistochemical staining of FGFR could be helpful in the differential diagnosis of solitary fibrous tumor, DFSP, aggressive fibromatosis, and undifferentiated sarcomas. The detection of FGFR protein expression by immunohistochemistry is important for targeted therapy of FGFR inhibitors.